Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(5):296-298; doi:10.1093/jnci/djj110
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Tuma, R. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tuma, R. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2006.

NEWS

Trastuzumab Faces Trials, Clinical and Otherwise

Rabiya S. Tuma

The first 150 words of the full text of this article appear below.

Last spring's eagerly anticipated interim results from three clinical trials of trastuzumab (Herceptin) showed that the use of the drug in the adjuvant setting cut the risk of relapse in half in early breast cancer patients. As the data continue to accumulate and mature, the benefit appears consistent and real, according to work presented at the San Antonio Breast Cancer Symposium in December. However, questions remain about how best to use trastuzumab, how to manage the cardiotoxicity that comes with its use, and how to make up for the fact that all the trials have been halted early, ruling out the possibility of gathering long-term survival data from a randomized setting.

Adding to the interim results from three other trials presented last year, Dennis Slamon, M.D., Ph.D., professor of hematology and oncology at the University of California Medical School in Los Angeles, presented the results from the first planned . . . [Full Text of this Article]

HERA Trial Update

Early Stoppage

Correlates of Response

Duration of Therapy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
B. J. Czerniecki, G. K. Koski, U. Koldovsky, S. Xu, P. A. Cohen, R. Mick, H. Nisenbaum, T. Pasha, M. Xu, K. R. Fox, et al.
Targeting HER-2/neu in Early Breast Cancer Development Using Dendritic Cells with Staged Interleukin-12 Burst Secretion
Cancer Res., February 15, 2007; 67(4): 1842 - 1852.
[Abstract] [Full Text] [PDF]